FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Discovery · preclinical Continuing brain-targeted RNA candidate discovery through a national drug development project and a university partnership.

  • Selected for a hit-stage project in the national drug development program. Source
  • Signed an agreement with Soonchunhyang University's AIBIOME program. Source

Roles often seen at this stageResearch & development · Data & AI · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

BIORCHESTRA

A developer of RNA medicines for neurological and rare diseases that owns the brain-targeted delivery platform BDDS and the candidate BMD-001.

BDDS

Technology platform

A brain-targeted polymer-based delivery platform, the subject of a joint research and option agreement worth up to USD 861 million with a global drugmaker in March 2023.

BMD-001

Stage unconfirmed

A brain-disease drug candidate pairing an RNA molecule with the BDDS platform.

Completion reported

Selected to carry out a hit-stage discovery project in the second 2026 round of the Korea Drug Development Fund program.

Completion reported

Signed an agreement with Soonchunhyang University's AIBIOME program on AI-based biopharmaceutical research and talent training.

Official role guide

BIORCHESTRA careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 순천향대, 바이오오케스트라와 AI 바이오의약품 전문인재 양성 맞손 ↗순천향대학교 · Published 2026-10-19 · Sources checked 2026-11-18 · Original unavailable
  2. 바이오오케스트라, 8억6100만 달러 규모 기술이전 계약 체결 ↗메디게이트뉴스 · Published 2023-03-28 · Sources checked 2026-11-18 · Original unavailable
  3. 2026년도 제2차 국가신약개발사업 과제 선정 공고문 ↗국가신약개발사업단 · Published 2026-10-08 · Sources checked 2026-11-18 · Original unavailable